Publications by authors named "Mary Spellman"

Claim this Profile
D
Diacerein 1% Ointment for the Treatment of Epidermolysis Bullosa Simplex: A Randomized, Controlled Trial.
Joyce Teng, Amy S. Paller, Anna L. Bruckner, Dedee F. Murrell, Jemima E. Mellerio, Mary Spellman

J Drugs Dermatol· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Investigator's Global Assessment of Chronic Prurigo: A New Instrument for Use in Clinical Trials.
Claudia Zeidler, Manuel P Pereira, Matthias Augustin, Mary Spellman, Sonja Ständer

Acta Derm Venereol· February 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Serlopitant for psoriatic pruritus: A phase 2 randomized, double-blind, placebo-controlled clinical trial.
David M Pariser, Jerry Bagel, Mark Lebwohl, Gil Yosipovitch, Elaine Chien, Mary C Spellman

J Am Acad Dermatol· June 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Diagnostic and treatment algorithm for chronic nodular prurigo.
Hartmut F Ständer, Sarina Elmariah, Claudia Zeidler, Mary Spellman, Sonja Ständer

J Am Acad Dermatol· February 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The NK1 receptor antagonist serlopitant for treatment of chronic pruritus.
Sonja Ständer, Mary C Spellman, Paul Kwon, Gil Yosipovitch

Expert Opin Investig Drugs· August 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tavaborole 5% Topical Solution for the Treatment of Toenail Onychomycosis in Pediatric Patients: Results from a Phase 4 Open-Label Study.
Phoebe Rich, Mary Spellman, Vivek Purohit, Chuanbo Zang, Tim J. Crook

J Drugs Dermatol· February 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term safety of crisaborole ointment 2% in children and adults with mild to moderate atopic dermatitis.
Lawrence F Eichenfield, Robert S Call, Douglass W Forsha, Joseph Fowler, Adelaide A Hebert, Mary Spellman

J Am Acad Dermatol· October 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of crisaborole ointment, a novel, nonsteroidal phosphodiesterase 4 (PDE4) inhibitor for the topical treatment of atopic dermatitis (AD) in children and adults.
Amy S Paller, Wynnis L Tom, Mark G Lebwohl, Robin L Blumenthal, Mark Boguniewicz, Mary C Spellman

J Am Acad Dermatol· September 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Phase 2, Randomized, Controlled, Dose-Ranging Study Evaluating Crisaborole Topical Ointment, 0.5% and 2% in Adolescents With Mild to Moderate Atopic Dermatitis.
Linda F Stein Gold, Lynda Spelman, Mary C Spellman, Matilda H Hughes, Lee T Zane

J Drugs Dermatol· December 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Anti-CD23 monoclonal antibody, lumiliximab, inhibited allergen-induced responses in antigen-presenting cells and T cells from atopic subjects.
Jill A Poole, Jianfeng Meng, Mitchell Reff, Mary C Spellman, Lanny J Rosenwasser

J Allergy Clin Immunol· October 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The efficacy and tolerability of clobetasol propionate foam 0.05% in the treatment of mild to moderate plaque-type psoriasis of nonscalp regions.
Alice B Gottlieb, Rosanne Odom Ford, Mary C Spellman

J Cutan Med Surg· June 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis